TrialInternational journal of clinical oncology2015

Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.

Yoshito Komatsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.